Call of Abstracts - "International conference on the E-Cigarette: patterns of use and health impacts"





Call of abstracts

"International conference on the E-Cigarette: patterns of use and health impacts" - Paris, on 5-6th December 2022

Submission form

Poster & oral presentation

Contact details of the corresponding author

Title

Ms

First name

Ailsa

Last name

Butler

E-mail

ailsa.butler@phc.ox.ac.uk

Institution / company

University of Oxford

Unit / department

Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences

Address

Nuffield Department of Primary Care Health Sciences, Radcliffe Observatory Quarter,, Woodstock Road Oxford, OX2 6GG United Kingdom

Background information

Type of submission

Oral or poster

Theme of conference

Patterns of use

Keywords

Harm reduction

Smoking cessation

Trajectories of users

Abstract title

E-cigarettes for smoking cessation: the latest Cochrane living systematic review evidence

Author's contact details:

Title

Ms

First name

Ailsa

Last name

Butler

E-mail

ailsa.butler@phc.ox.ac.uk

Institution / company

University of Oxford

Co-author's contact details:

Number of co-authors

3

Co-author 1

Nicola Lindson Oxford University

Co-author 2

Jamie Hartmann-Boyce Oxford University

Co-author 3

On behalf of the Cochrane living systematic review team Oxford University, University of London, University of East Anglia, University of Auckland, Harvard Medical School, University New South Wales

Abstract details (poster & oral)

Background, method, results and conclusions

Background: When investigating e-cigarettes (EC) for smoking cessation, three of the most policy relevant questions relate to effectiveness, safety and long-term use. We will present the latest available evidence on these outcomes from the Cochrane living review of EC for smoking cessation, currently under update.

Methods: We search monthly for studies testing EC interventions for smoking cessation in people who smoke combustible tobacco cigarettes (CC). Studies had to report abstinence from CC at 6 months or longer &/or data on adverse events or other markers of safety at 1 week follow-up or longer. We carried out screening and data extraction in duplicate, according to Cochrane methods.

Results: At time of writing, we have identified 75 studies (n=19076) eligible for inclusion. We will report

the latest evidence on the effectiveness, tolerability & safety of using EC to help people who smoke CC achieve long-term smoking abstinence. Our main comparators are EC vs NRT; nicotine EC vs non-nicotine EC; & EC vs behavioral support or no support. We will also report on the patterns of longer-term EC use and health impacts in terms of levels of toxicants among people using EC compared to continued use of CC in stop smoking trials. We will report results of our recent meta-analysis of the prevalence of continued EC use among individuals allocated to EC conditions (54%), and among those individuals who had successfully guit CC (70%).

Conclusions: We will present the most up-to-date data from our living systematic review. Our current data consistently signal benefit of nicotine EC for smoking cessation and do not show any clear evidence of harm. We found substantial numbers of people who use EC in quit attempts continue to use them for at least 6 months, with higher long-term use in people who successfully quit. Further research is needed to establish drivers of variation in and implications of continued use of EC, including longer-term studies investigating potential harms.

Main messages

Data consistently signal benefit of nicotine EC for smoking cessation, with no clear evidence of short-term harms. More than half of people given an EC to stop smoking are likely to still be using them 6 months later.

Type of study / research

Systematic review

Geography of the study

International (including Europe)

Funding of study

Federal source

Yes

State source

No

Nonprofit Grant Funding Entity Source

Yes

Nonprofit Grant Funding Entity Source

Yes

Academic Institution Source

Yes

Pharmaceutical Industry Source

No

Tobacco/E-Cigarette Industry Source

No

Declaration of interest

The submitter declares that during the past 5 years have a direct nor indirect link (professional*, personal or financial**) with the tobacco and e-cigarette companies

No